FDA to meet Novo Nordisk on troubled site; AbbVie buys drug-device factory news2026-01-15T13:52:56+00:00January 15th, 2026|Endpoints News|
Ocugen touts Phase 2 data for eye disease gene therapynews2026-01-15T13:15:39+00:00January 15th, 2026|Endpoints News|
J&J reports positive Phase 3 data for Tecvayli in earlier blood cancer settingnews2026-01-15T11:52:54+00:00January 15th, 2026|Endpoints News|
Novo Nordisk Foundation to inject $850M+ into BioInnovation Institute through 2035news2026-01-15T08:30:28+00:00January 15th, 2026|Endpoints News|
Scribe Therapeutics plans to test cholesterol-lowering therapy this summernews2026-01-14T21:11:18+00:00January 14th, 2026|Endpoints News|
Manufacturers benefit as pharma customers invest back in USnews2026-01-14T20:19:22+00:00January 14th, 2026|Endpoints News|
Jazz sells priority review voucher for $200M, scoring highest price in a decadenews2026-01-14T18:44:04+00:00January 14th, 2026|Endpoints News|
Health tech funding rounds get bigger when Andreessen Horowitz and General Catalyst joinnews2026-01-14T18:43:51+00:00January 14th, 2026|Endpoints News|
#JPM26: Drugmakers want US reforms, not to slow down Chinanews2026-01-14T16:10:57+00:00January 14th, 2026|Endpoints News|
ImmunityBio’s Anktiva lung cancer data; Glaukos’ glaucoma implant sales disappointnews2026-01-14T16:08:20+00:00January 14th, 2026|Endpoints News|
